Context Therapeutics (NASDAQ:CNTX) Inc. CEO Martin Lehr joined Proactive to discuss the Philadelphia, Pennsylvania-based oncology company's preclinical data from two pipeline programs. Lehr says these include in vivo combination and immunomodulation data evaluating onapristone extended release (ONA-XR), the company’s lead clinical program. The data are being presented at the American Association for Cancer Research (AACR) Annual Meeting 2022. Context will host a webinar with AACR presenters on Wednesday, April 13, 2022, at 11 a.m. ET. Interested parties can view the webinar by registering here: https://edisongroup.zoom.us/webinar/register/WN_AczVH-d_QMy5qcT_enL3ww
Context Therapeutics reveals preclinical data from two pipeline programs
